{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:46:40Z","timestamp":1792072000501,"version":"4.4.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To examine real-world patterns of systemic hormone therapy (HT) initiation and continuation among women with a diagnosis of menopause.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Using the Merative\u2122 MarketScan\u00ae Research Databases (2009\u20132022), we identified women aged 45\u201360 years with menopause-related claims and at least 12 months of continuous enrollment. Patients with bilateral oophorectomy, breast or gynecologic cancers, or HT contraindications were excluded. Multivariable regression analyzed factors associated with HT initiation, formulation, and duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Of 318,621 eligible women, 21.7% initiated systemic HT within 1 year. Predictors of HT initiation included younger age (adjusted odds ratio [aOR] 2.17; 95% CI, 2.12\u20132.23), prior hysterectomy (aOR 1.98; 95% CI, 1.77\u20132.21), and local hormone use (aOR 3.25; 95% CI, 3.05\u20133.47). Initiation was significantly lower among women with obesity (aOR 0.78; 95% CI, 0.75\u20130.81), diabetes (aOR 0.69; 95% CI, 0.66\u20130.72), and Black racial identification (aOR 0.78; 95% CI, 0.68\u20130.89). Initial formulations were estrogen plus progestogen (52.5%), estrogen-alone (32.4%), and progestogen-alone (15.1%). The median first-episode duration was 6.6 months; 38.8% of patients continued at 12 months. Black racial (adjusted hazard ratio [aHR] 1.52; 95% CI, 1.34\u20131.73) and Hispanic ethnic (aHR 1.43; 95% CI, 1.14\u20131.80) identities predicted faster discontinuation. Conversely, prior hysterectomy (aHR 0.75; 95% CI, 0.68\u20130.83) and concurrent local hormone use (aHR 0.84; 95% CI, 0.80\u20130.89) reduced discontinuation risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Although one-fifth of women initiated systemic HT shortly after their diagnosis, low persistence and racial disparities among those who initiated reveal critical gaps in long-term menopause management. Furthermore, true real-world utilization is likely even lower due to underdocumentation in clinical coding. These findings underscore an urgent need for targeted, equitable interventions to improve treatment adherence and ensure consistent, comprehensive care for menopausal women.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/aog.0000000000006386","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T01:00:14Z","timestamp":1784854814000},"page":"e318-e328","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Initiation and Duration of Systemic Hormone Therapy for Menopausal Symptoms"],"prefix":"10.1097","volume":"148","author":[{"given":"Intira","family":"Sriprasert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongmei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Shoupe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan L.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"R1-20261015","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.2105\/AJPH.2005.066936","article-title":"Longitudinal analysis of the association between vasomotor symptoms and race\/ethnicity across the menopausal transition: study of women's health across the nation","volume":"96","author":"Gold","year":"2006","journal-title":"Am J Public Health"},{"key":"R2-20261015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1001\/jamainternmed.2014.8063","article-title":"Duration of menopausal vasomotor symptoms over the menopause transition","volume":"175","author":"Avis","year":"2015","journal-title":"JAMA Int Med"},{"key":"R3-20261015","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/GME.0000000000002028","article-title":"The 2022 hormone therapy position statement of the North American Menopause Society","volume":"29","year":"2022","journal-title":"Menopause"},{"key":"R4-20261015","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women\u2014principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R6-20261015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1001\/jama.2025.22259","article-title":"Updated labeling for menopausal hormone therapy","volume":"335","author":"Makary","year":"2026","journal-title":"JAMA"},{"key":"R7-20261015","doi-asserted-by":"crossref","first-page":"e243128","DOI":"10.1001\/jamahealthforum.2024.3128","article-title":"Menopausal hormone therapy use among postmenopausal women","volume":"5","author":"Yang","year":"2024","journal-title":"JAMA Health Forum"},{"key":"R8-20261015","doi-asserted-by":"crossref","first-page":"e243135","DOI":"10.1001\/jamahealthforum.2024.3135","article-title":"Recent trends in menopausal hormone therapy use in the US: insights, disparities, and implications for practice","volume":"5","author":"Iyer","year":"2024","journal-title":"JAMA Health Forum"},{"key":"R9-20261015","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.122.061559","article-title":"Rethinking menopausal hormone therapy: for whom, what, when, and how long?","volume":"147","author":"Cho","year":"2023","journal-title":"Circulation"},{"key":"R10-20261015","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/humupd\/dmy039","article-title":"The route of administration, timing, duration and dose of postmenopausal hormone therapy and cardiovascular outcomes in women: a systematic review","volume":"25","author":"Oliver-Williams","year":"2019","journal-title":"Hum Reprod Update"},{"key":"R12-20261015","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/GME.0000000000002648","article-title":"Documentation of menopause-related International Classification of Diseases codes in the electronic health record in midlife women with menopause symptoms","volume":"33","author":"Karam","year":"2026","journal-title":"Menopause"},{"key":"R13-20261015","doi-asserted-by":"crossref","first-page":"737","DOI":"10.3109\/13697137.2015.1037267","article-title":"Discontinuation rates of menopausal hormone therapy among postmenopausal women in the post-WHI study era","volume":"18","author":"Kyvernitakis","year":"2015","journal-title":"Climacteric"},{"key":"R14-20261015","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/gme.0b013e318154b9a5","article-title":"Hormone therapy initiation after the Women's Health Initiative","volume":"15","author":"Newton","year":"2008","journal-title":"Menopause"},{"key":"R15-20261015","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/gme.0b013e31826f80e0","article-title":"Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials","volume":"20","author":"Wild","year":"2013","journal-title":"Menopause"},{"key":"R16-20261015","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/j.1463-1326.2005.00545.x","article-title":"Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women","volume":"8","author":"Salpeter","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"R17-20261015","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s13300-024-01546-1","article-title":"Menopausal hormone therapy in women with type 2 diabetes mellitus: an updated review","volume":"15","author":"Paschou","year":"2024","journal-title":"Diabetes Ther"},{"key":"R18-20261015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2217\/17455057.5.2.127","article-title":"Menopausal symptoms and ethnicity: the Study of Women's Health across the nation","volume":"5","author":"Green","year":"2009","journal-title":"Womens Health (Lond)"},{"key":"R19-20261015","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1097\/GME.0000000000000676","article-title":"Characterizing the trajectories of vasomotor symptoms across the menopausal transition","volume":"23","author":"Tepper","year":"2016","journal-title":"Menopause"},{"key":"R20-20261015","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/GME.0000000000001978","article-title":"Racial\/ethnic disparities in the diagnosis and management of menopause symptoms among midlife women veterans","volume":"29","author":"Blanken","year":"2022","journal-title":"Menopause"},{"key":"R21-20261015","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1007\/s40615-024-02209-4","article-title":"Health disparities and hormone therapy prescribing for early, peri-and postmenopausal women: a scoping review","volume":"12","author":"Conklin","year":"2025","journal-title":"J Racial Ethn Health Disparities"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:02:25Z","timestamp":1792069345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000006386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000006386","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"2026-04-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}